Table 2.

Novel hybrid therapeutic compounds against AD

Hybrid compound	AChE inhibitor		β-amyloid antiaggregation	Antioxidant	Other activities	IC50 value	Clinical study	References
Amentoflavone			✔□		NA	0.26 µM	In vitro	[93]
N-(3-((Benzyl(methyl)amino)methyl)phenyl)-6,7-dimethoxy-4-oxo-4H-chromene-2-carboxamide Cpd 17		✔□			NA	4.5 µM	In vitro and in silico	[94]
Cpd18, berberine linked to phenol by 4-carbon spacers		✔□			NA	0.097 µM	In vitro and in silico	[99]
Berberine-pyrocatechol hybrid (compound 19)		✔□			NA	0.123 µM	In vitro	[100]
Berberine-hydroquinone hybrid (compound 20)		✔□	✔□	✔□	NA	0.460 μM	In vitro	[100]
Ber-D Cpd 21				✔□	Cu chelation, reduces cellulo multifaceted toxicity in AD	NA	In vitro and in silico	[101]
Bis(9)-( −)-Meptazinol (B9M)		✔□	✔□		NA	3.9 nM	In vitro	[102]
Ferulic acid-memoquin hybrids, Cpd 22		✔□	✔□	✔□	Can cross the BBB	3.2 μM	In vitro	[103]